Effect of Thickened Feeds on Swallow Physiology in Children With Dysphagia
Launched by BOSTON CHILDREN'S HOSPITAL · Aug 6, 2020
Trial Information
Current as of July 12, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how different thickness levels of liquids affect swallowing in children who have difficulty swallowing, known as dysphagia. The study specifically focuses on infants and children who have experienced a first-time unexplained event where they might have had trouble breathing or swallowing. By adjusting the thickness of their liquids, the researchers hope to learn how it impacts their ability to swallow safely.
To participate in this study, children aged 0 to 21 years who have been admitted to Boston Children's Hospital for swallowing difficulties or related issues may be eligible. Participants will likely have a special swallowing test done, called a videofluoroscopic swallow study, to assess how well they can swallow different types of liquids. It's important to note that children with certain medical conditions or allergies to the thickening agents used in the study may not be able to join. Overall, this trial aims to help improve swallowing safety in children with dysphagia.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 0 to 21 years
- • Admitted to Boston Children's Hospital after experiencing first lifetime BRUE, or with dysphagia symptoms such that they would be at risk for BRUE or other symptoms of swallowing difficulty
- • Have had videofluoroscopic swallow study performed or might have future videofluoroscopic swallow study performed.
- Exclusion Criteria:
- • Any pre-existing medical diagnoses that exclude brief resolved unexplained event diagnosis including seizure disorders and cyanotic congenital heart disease
- • Any nasal/pharyngeal/esophageal anomalies that might affect safe placement of the pharyngeal motility catheter
- • Children fed exclusively by enteral tube
- • Allergy to rice cereal or Gelmix thickener, which will be used to adjust liquid viscosity
About Boston Children's Hospital
Boston Children's Hospital is a leading pediatric healthcare institution renowned for its commitment to advancing child health through innovative research and exceptional clinical care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise in pediatric medicine to conduct rigorous and ethically sound research studies aimed at improving treatment options and outcomes for children. With a collaborative approach that integrates cutting-edge technology and multidisciplinary teams, Boston Children's Hospital is dedicated to translating scientific discoveries into practical applications that enhance the well-being of young patients and their families.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Trial Officials
Daniel R Duncan, MD, MPH
Principal Investigator
Boston Children's Hospital
Rachel Rosen, MD, MPH
Study Director
Boston Children's Hospital
Sudarshan Jadcherla, MD
Study Director
Nationwide Children's Hospital
Taher Omari, PhD
Study Director
Flinders University
Samuel Nurko, MD, MPH
Study Director
Boston Children's Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials